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RECENT ANATOMIC AND FUNCTIONAL DATA indicate that intracardiac ganglia possess a population of neurons that are heterogeneous with regard to morphology as well as electrophysiological and pharmacological properties including associated neurotransmitters and phenotypes (12, 13, 16, 17, 37) .
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a recently discovered neuropeptide that was isolated originally from the ovine hypothalamus (23) . Interestingly, PACAP and vasoactive intestinal peptide are members of a family of structurally related regulatory neuropeptides (24) . PACAP exhibits multiple actions in the central nervous system and in various peripheral organs including the endocrine glands, the airways, and the cardiovascular and immune systems (32) . For example, PACAP stimulates pancreatic enzyme secretion in sheep via activation of vagal cholinergic neurons (26) and also stimulates catecholamine release from the adrenal gland in anesthetized dogs (11) . Several studies (5, 31, 35) have demonstrated that PACAP and its receptors exist in the heart and in intrinsic cardiac nerves and that PACAP increases cardiac ganglion neuron membrane excitability. We previously demonstrated (14, 15) that PACAP evoked negative chronotropic and inotropic responses in the canine heart. The PACAPinduced negative cardiac effects were prevented by atropine and tetrodotoxin but not by hexamethonium. These findings indicate that ACh release from intracardiac postganglionic parasympathetic nerves participates in the cardiac response to PACAP (14, 15) . In addition, Braas et al. (5) recently demonstrated that almost all postganglionic parasympathetic neurons in the guinea pig heart express membrane-associated PACAP receptor proteins. Therefore, PACAP may participate in the intrinsic neural regulation of heart function.
Numerous physiological studies have documented the nonuniform effects of vagal stimulation on atrial tissue (1, 6, 25, 30, 38) . However, whether the effects of PACAP on atrial tissue vary in different regions of the atria is unknown. We hypothesized that PACAP directly activates the intrinsic cardiac nerves and has a different effect than cervical vagal stimulation. Therefore, the present study was designed to assess the effects of PACAP on different atrial sites.
METHODS
The experiments performed in this study were approved by the Institutional Animal Care and Use Committee of Case Western Reserve University.
General methods. Twenty-six mongrel dogs of either sex (weight 25-29 kg) were anesthetized with pentobarbital sodium (30 mg/kg iv). Supplemental doses were given to maintain stable anesthesia. A tracheal cannula was inserted and intermittent positive-pressure ventilation was administered by a respirator with room air (model 607; Harvard Apparatus; Millis, MA). Body temperature was maintained at 37.0°C. The chest was opened transversely at the fifth intercostal space and a pericardial cradle was created. Cervical vagal nerves were isolated bilaterally via a midline neck incision and crushed with tight ligatures. Each stellate ganglion was isolated and crushed at its junction with the ansa subclavia. These maneuvers remove almost all tonic neural activity to the heart (21). Four bipolar electrodes were placed on four atrial epicardial sites. To stimulate the parasympathetic nerves to the heart, bipolar stainless steel wire electrodes were inserted in the cardiac end of each cervical vagal nerve, and the wires were connected to an electrical stimulator (model S8800; Grass Instruments). Catheters were inserted into the right femoral artery and vein to record the arterial blood pressure and to inject drugs, respectively. A catheter was inserted into the left atrium through the left atrial appendage to inject the PACAP. The heart rate was derived from the standard electrocardiogram (ECG) lead II. The ECG, heart rate, and femoral arterial blood pressure were monitored continuously throughout the experiments (CardioLab; Prucka Engineering; Houston, TX).
An electrode array containing 95 bipolar electrodes (48 pairs for the right atrium, 36 pairs for the left atrium, and 11 pairs placed separately on Bachmann's bundle) was used to record atrial electrical activation (see Fig. 1 ). The interelectrode distance of each bipolar electrode in the array was 1.2 mm, and the distance between the center of each bipolar electrode pair and its neighbor was 7 mm longitudinally and 6 mm transversally. The electrode array for Bachmann's bundle was placed under the aortic root to cover the anterior aspect of the atrial appendages and Bachmann's bundle. The array containing 84 bipolar electrodes was placed around the atria and secured with a hook-and-loop (Velcro) belt. Each electrogram signal was filtered (0.3-500 Hz), digitized (12-bit resolution and 1-kHz sampling rate), transmitted into a microcomputer (Compaq), and saved to CD-ROM. Software developed in our laboratory was used to analyze each electrogram signal and generate activation maps. Each electrogram was analyzed with computer-determined peak-amplitude criteria and was verified manually.
Electrophysiological measurements. Programmed atrial stimulation was performed from four atrial sites: the high right atrium (HRA), the low right atrium (LRA), the high left atrium (HLA), and the low left atrium (LLA) (see Fig. 1 ). Pacing was performed using 2-ms square pulses at twice the diastolic threshold. An eight-beat drive train (S 1) at a basic cycle length (BCL) of 300 ms was followed by a premature stimulus (S 2). The coupling interval was progressively increased by 10-ms increments until atrial capture occurred. The effective refractory period (ERP) was defined as the longest S 1-S2 interval that failed to produce a propagated response. The ERP measurement was started 30 s after the onset of vagal stimulation or 60 s after PACAP injection (see Fig. 2 ). The ERP measurement was started at a coupling interval close to the ERP and was performed in 15 s. If the ERP measurement was not determined in 15 s, the measurement was repeated after adequate recovery time. Heart rate was measured immediately before programmed stimulation was started (see Fig. 2 ). In addition, we determined the minimum atrial fibrillation (AF) cycle length at each of 12 electrode sites (6 right atrial sites and 6 left atrial sites). This measurement can be used to predict the distribution of atrial refractoriness (19) and was calculated by averaging the two shortest electrogram intervals recorded from an electrode during a 2-s interval of AF. Electrograms were carefully analyzed to reject low-amplitude potentials and to detect double potentials associated with block. Correlation with the surface ECG was used to eliminate ventricular electrograms. AF was induced by a single premature extra stimulus delivered at 10 ms longer than the ERP at each site used for ERP determination. The initiation of AF was defined as a rapid (Ͼ400 beats/min) irregular atrial rhythm persisting spontaneously for Ͼ1 min.
Conduction velocity was measured during constant pacing at 300 ms. The regional conduction velocity was determined in the vicinity of the stimulating electrode (beginning at least 14 mm from the pacing site to avoid virtual cathode effects). We analyzed activation times at a series of electrode sites in each atrium (see Fig. 1 ). The distance of each site from the first of the series of electrodes was plotted against activation time, and conduction velocity was determined using linear regression. The activation sequence of the paced beat was analyzed to ensure that impulse propagation was linear. A minimum of three electrode sites was used for each analysis, and the correlation coefficient between activation time and distance always exceeded 0.99. The average of two beats was used to calculate conduction velocity for each determination. For each experiment, the same sites were used to measure conduction velocity.
Nerve stimulation and PACAP administration. In the present experiments, the right and left cervical vagal nerves were stimulated simultaneously to decrease the sinus rate by ϳ30 and 50%; such stimulations were defined as low-and high-intensity vagal stimulations, respectively. Low-intensity cervical vagal nerve stimulation was performed with 10-mA pulse amplitude at a frequency of 3 Hz. Pulse durations of 0.03 or 0.04 ms were used to achieve the desired heart rate decrease (30%). High-intensity vagal stimulation , and low left atrium (LLA) pacing sites, respectively. These pacing electrodes were used for effective refractory period (ERP) and conduction velocity (CV) measurements. Bipolar electrodes indicated by numbers were used for CV and minimum atrial fibrillation cycle length (mAFCL) measurements. BB, Bachmann's bundle; LAA, left atrial appendage; RAA, right atrial appendage; SVC, superior vena cava; IVC, inferior vena cava; PV, pulmonary vein; AVR, atrioventricular ring.
was performed with a 12-mA pulse amplitude at a frequency of 5 Hz. Pulse durations of 0.04 or 0.05 ms were used to achieve the desired heart rate decrease (50%). PACAP (5-10 nmol) was injected into the left atrium to decrease the sinus rate by ϳ30%. The changes in heart rate in response to vagal stimulation and PACAP administration were stable during the time course of ERP measurement. The intensity of vagal nerve stimulation and the dose of PACAP were adjusted before each experiment to achieve consistent changes in heart rate in response to those interventions through the experiments. The effects of vagal stimulation or PACAP administration on heart rate were stable through the experiment.
Experimental protocol. Experiments were performed in 26 autonomically decentralized hearts of open-chest anesthetized dogs. After 30 min of postsurgical stabilization, two series of experiments were performed. In one series of experiments, we examined the effects of low-intensity cervical vagal stimulation (n ϭ 5) and PACAP administration (n ϭ 5) on the ERP and conduction velocity at 4 atrial sites in 10 dogs. A 2-to 4-s interval of AF was recorded from the atrial electrode array to measure the minimum AF cycle length (mAFCL) 2 min after vagal stimulation started or after PACAP administration (n ϭ 8) at 12 atrial sites. In another six dogs, we examined the effects of high-intensity cervical vagal stimulation on the ERP at two atrial sites, namely, the HRA and the HLA.
Our previous experiments (14, 15) showed that in addition to releasing ACh from parasympathetic nerves, PACAP directly activates the sinus node cells and atrial muscle and causes positive chronotropic and inotropic effects in dog heart. Because of this, the second series of experiments was designed to determine whether direct cardiac effects of PACAP participate in the changes in atrial ERP. In a separate group of 10 dogs, at each of the four sites we tested the effects of each intervention (n ϭ 5) on ERP after atropine treatment (0.3 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 iv). In this group of experiments, to confirm the effects of vagal stimulation and PACAP administration on the heart rate, cervical vagal nerves were stimulated and PACAP was also administered before atropine treatment.
During ERP measurement, the P-R interval, QRS complex duration, and Q-T interval were measured from ECG lead II during constant pacing at a BCL of 300 ms in four dogs. In addition, the mean arterial blood pressure (MABP) was measured immediately before the ERP measurement was started in 20 experiments.
Because PACAP induces tachyphylaxis in neonatal pig hearts (27) , adequate recovery times were allowed between PACAP administrations. To minimize time-dependent changes in atrial ERP, each dog was randomly assigned to undergo programmed stimulation at only two of the four atrial sites. The basal ERP and arterial blood pressure of the control conditions did not change during the protocol.
Data analysis. All data are shown as means Ϯ SE. An ANOVA with Bonferroni's test was used for the statistical analysis of multiple comparisons of data. Student's t-test for paired or unpaired data was used to compare the two groups. P values Ͻ0.05 were considered statistically significant.
Drugs. Drugs were mixed just before each experiment. PACAP (PACAP-27; Peninsula Laboratories) was dissolved in distilled water. Atropine sulfate (Sigma; St. Louis, MO) was dissolved and diluted in 0.9% NaCl. Drugs were injected into the left atrium or the right femoral vein.
RESULTS

Effects of vagal stimulation and PACAP on heart
rate. Low-intensity vagal stimulation decreased the mean heart rate from 116 Ϯ 2.5 to 77 Ϯ 2.3 beats/min (P Ͻ 0.001). High-intensity vagal stimulation decreased the mean heart rate from 114 Ϯ 4.6 to 56 Ϯ 2.4 beats/min (P Ͻ 0.001). PACAP decreased the mean heart rate from 116 Ϯ 2.5 to 79 Ϯ 3.3 beats/min (P Ͻ 0.001). The mean heart rate measurements during low-intensity vagal stimulation and after PACAP administration were not statistically different. Atropine prevented the decreases in heart rate in response to vagal stimulation and PACAP administration (P Ͻ 0.001). After atropine treatment, PACAP increased the heart rate from 114 Ϯ 6 to 181 Ϯ 7 beats/min (P Ͻ 0.001). Effects of PACAP on atrial ERP and conduction velocity. In the control state, the ERP at the four sites tested were not significantly different. During lowintensity vagal stimulation, the ERP shortened in the HRA but not in the LRA, HLA, or LLA (see Fig. 3A ). During high-intensity vagal stimulation, the ERP shortened more in the HRA than in the HLA (P Ͻ 0.001; see Fig. 3B ). In contrast, after PACAP administration, the ERP shortened to a similar extent at all atrial sites tested (see Fig. 3C ). These results indicate that cervical vagal stimulation had nonuniform effects on the atrial ERP, whereas the effect of PACAP on the ERP was uniform in both atria. As an additional measure of ERP, mAFCL was calculated for 12 atrial sites. The mAFCL was shorter in the HRA and right atrial appendage than in the left atrium (P Ͻ 0.05) 2 min after the low-intensity vagal stimulation was started (see Fig. 4A ). In contrast, the mAFCL in the right atrium was similar to that in the left atrium 2 min after the PACAP injection (see Fig. 4B ). In addition, AF terminated ϳ4 min after PACAP was injected. These data are consistent with the ERP measurements and suggest that the duration of the effect of PACAP on atrial refractoriness is probably ϳ4 min.
In the control condition, conduction velocity did not differ between pacing sites. PACAP tended to increase conduction velocity at the right atrium and HLA, but these responses were not statistically significant (see Fig. 5 ). Vagal stimulation did not change conduction velocity regardless of the atrial site tested (see Fig. 5 ).
Low-intensity vagal stimulation did not shorten the ERP at any site after atropine administration (see Fig.  6A ). After atropine treatment, PACAP tended to shorten the ERP in the HRA (P ϭ 0.065) and the HLA (P ϭ 0.199), but these responses were not statistically significant (see Fig. 6B ). PACAP did not shorten the ERP in the other two sites. 
Effects of PACAP on ECG intervals and MABP. P-R intervals during low-intensity vagal stimulation and
after PACAP administration were significantly longer than those measured in the control condition in four non-atropine-treated dogs (see Table 1 ). In addition, the QRS complex duration was shorter after PACAP administration than during low-intensity vagal stimulation and during control condition in the same four dogs. However, the Q-T interval was the same regardless of the intervention. MABP did not differ regardless of the interventions in 10 non-atropine-treated dogs, whereas it increased significantly after PACAP administration in 10 atropine-treated dogs (see Table 1 ).
DISCUSSION
In this study, we found that cervical vagal stimulation caused nonuniform effects on atrial ERP, whereas PACAP caused uniform effects on atrial ERP (see Fig.  3 ). The effects of vagal stimulation on ERP were similar to those of PACAP in the HRA, but not in the other three sites (see Fig. 3 ). The effects of PACAP on atrial refractoriness during AF were uniform in both atria but those of vagal stimulation were not (see Fig. 4 ). Conduction velocity did not change during any intervention regardless of the atrial site tested (see Fig. 5 ). After atropine treatment, none of these interventions shortened the atrial ERP in any of the four sites tested (see Fig. 6 ). These results demonstrate that PACAP shortens atrial refractoriness uniformly in different regions of both atria.
Effect of PACAP on ERP. Previous studies have shown that cervical vagal stimulation elicits nonuniform effects on atrial ERP (1, 6, 38) . Zipes et al. (38) showed that when supramaximal cervical vagal stimulation diminished the sinus rate to a value Ͻ30 per minute, it shortened the atrial ERP mainly in the right atrium. However, in the present study, administration of PACAP caused uniform shortening of the ERP in both atria (see Fig. 3 ). In addition, after PACAP administration, mAFCL at 12 atrial sites were similar in both atria (see Fig. 4 ). This finding provides additional evidence for spatial uniformity in atrial refractory properties after PACAP administration. Our previous results (14, 15) suggested that the PACAP-induced negative chronotropic and inotropic responses in the canine right atrium were caused by the release of ACh from intracardiac postganglionic parasympathetic nerves. The results of the present study suggest that PACAP causes uniform atrial ERP shortening by activating intracardiac postganglionic nerves that are not activated by cervical vagal stimulation.
Previous investigators (6, 38) showed that the nonuniform atrial ERP shortening induced by vagal stimulation was caused by regional differences in the pattern of vagal innervation. In addition, Yuan et al. (37) demonstrated anatomically that 1) the majority of canine cardiac ganglionated plexuses are located in four atrial and three ventricular regions, 2) the number of ganglia in each plexus is variable, and 3) many neurons have features (plentiful cytoplasm and many organelles) that are typical of autonomic neurons. Therefore, there are regional differences in nerve innervation on the atria. Given the heterogeneous distribution of the ganglionated plexuses and the nonuniform shortening of atrial ERP caused by vagal stimulation, one might expect PACAP to exert a heterogeneous effect on atrial refractoriness. However, we found that compared with vagal stimulation, PACAP caused relatively uniform ERP shortening. Braas et al. (5) have shown that in the guinea pig heart, cardiac ganglia neuronal plasma membranes express PACAP receptor proteins, and PACAP increases cardiac ganglion neuron membrane excitability. Recent physiological studies indicate that cardiac ganglia contain [in addition to efferent parasympathetic postganglionic neurons (3)] afferent neurons (2) and local circuit neurons (4). In addition, Yuan et al. (37) inferred from their anatomic data that the canine intrinsic cardiac nervous system contains a variety of neurons interconnected via nerve plexuses and complex interactions can occur within intrinsic cardiac ganglia. They concluded that canine intrinsic cardiac neurons are more numerous and widely distributed than has been thought previously. Therefore, PACAP may cause relatively uniform ERP shortening in both atria through interactions of a variety of neurons in the cardiac ganglia.
In the present study, we observed that atropine inhibited the atrial ERP shortening in response to PACAP (see Fig. 6 ). We cannot exclude the possibility that PACAP caused uniform shortening of the ERPs in both atria via the activation of intracardiac muscarinic receptors. However, our previous studies (14) showed that the negative chronotropic and inotropic responses to PACAP injected directly into the sinus node artery were blocked by tetrodotoxin but not by hexamethonium. In addition, AF induction by PACAP was also abolished by tetrodotoxin but not by hexamethonium, propranolol, and phentolamine (15) . These results suggest that PACAP-induced neural release of ACh causes the negative chronotropic and inotropic effects and the induction of AF. It is well known that the induction of AF is associated with atrial ERP shortening (33) . Therefore, it is most likely that PACAP shortened the atrial ERP as a result of ACh released from intracardiac postganglionic nerves.
Direct cardiac effects of PACAP. In our previous studies, PACAP directly activated the atrial muscle and increased atrial contractility after atropine treatment in the isolated canine right atrial preparation (14) . However, whether PACAP shortens atrial ERP by direct effects on atrial tissue is not known. Several studies have indicated that the direct effects on cardiac tissue are mediated by cAMP. Ross-Ascuitto et al. (27) showed that 3-isobutyl-1-methylxanthine, a nonspecific phosphodiesterase inhibitor, augmented the increase in the maximal rate of change of left ventricular pressure in response to PACAP in neonatal pig hearts. In addition, PACAP increased cAMP in several tissues (23, 28) . ␤-Adrenergic stimulation increases cAMP and shortens atrial ERP (22, 30) . The shortening of atrial ERP is related to the augmentation of relaxation after the increase in cAMP. Therefore, PACAP may shorten atrial ERP directly by increasing tissue cAMP. To confirm whether PACAP shortens atrial ERP via a direct effect on atrial tissue, we studied the effects of PACAP on atrial ERP after atropine treatment. PACAP did not shorten atrial ERP after atropine treatment in our study (see Fig. 6 ). This demonstrates that PACAP does not shorten ERP by a direct effect on atrial tissue. Our results indicate that atrial ERP shortening in response to PACAP is associated with the activation of intracardiac postganglionic parasympathetic nerves rather than a direct effect on atrial tissue.
Intrinsic cardiac nervous system and PACAP. Cardiac function is regulated by the autonomic nervous system. The magnitude of the cardiac response to stimulation of the stellate ganglia and vagus nerves parallels the density of sympathetic and parasympathetic nerves in the heart, respectively (20) . This relatively simple description of autonomic cardiac control has been complicated by recent demonstrations of various neuropeptides (neuropeptide Y, somatostatin, substance P, and vasoactive intestinal peptide), which have been associated with intrinsic cardiac neurons histochemically (9, 10, 29, 36) . PACAP is a newly discovered neuropeptide that was isolated originally from the ovine hypothalamus (23) . Several studies (5, 31, 35) demonstrated that PACAP and its receptor exist in the heart and in intrinsic cardiac nerves and that PACAP increases cardiac ganglion neuron membrane excitability. Our present results indicate that PACAP directly activates the intrinsic cardiac nerves and has a different effect on atrial ERP than does cervical vagal stimulation. Therefore, PACAP may act as a modulator for the regulation of heart function through the interactions that occur within the intrinsic cardiac nervous system.
Our previous study (15) demonstrated that PACAP spontaneously induced AF in anesthetized dogs. ERP shortening is an important factor influencing induction of AF (33) .
The present study demonstrates that PACAP shortens atrial ERP in both atria. These effects of PACAP on atrial ERP probably participate in the induction of AF. Coumel (7, 8) has shown that in humans, some paroxysmal AF is associated with high parasympathetic tone. PACAP may have some role in generating the arrhythmia in these patients.
Study limitations. Because PACAP was injected into the left atrium, we cannot be certain that the drug was distributed evenly within the coronary vascular tree and the atrial myocardium. Thus we cannot exclude the possibility that PACAP was distributed preferentially to certain atrial sites. However, left atrial injection provided a simple, reproducible means for infusing PACAP. Aortic or coronary artery injection would have been cumbersome and perhaps less reliable. In addition, the response to PACAP injection was consistent among dogs. Hence the drug appeared to be distributed evenly throughout the coronary circulation and the atrial myocardium.
In the present study, MABP did not differ regardless of the interventions in 10 non-atropine-treated dogs, whereas it increased significantly after PACAP administration in 10 atropine-treated dogs (see Table 1 ). In addition, PACAP caused changes in ECG parameters including the P-R interval and the QRS complex duration (see Table 1 ). Furthermore, PACAP has several cardiovascular effects in the dog such as a vasodilata-tion, catecholamine release from the adrenal gland, and increased blood pressure (11, 15, 18) . Therefore, although PACAP is likely to cause atrial ERP shortening primarily due to interactions with a variety of neurons in the intracardiac ganglia, we cannot exclude the possibility that other cardiovascular effects of PACAP participate in the atrial ERP shortening in the present study.
Although the normal serum concentration (i.e., circulating levels) of PACAP in the dog has not yet been established, in humans it is a few picomoles (34) . Therefore, the high doses of PACAP used in the present study may not be physiologically relevant in the normal condition. In addition, circulating PACAP may not affect the atrial ERP under normal physiological conditions. However, Braas et al. (5) demonstrated that PACAP and its receptors were localized to intrinsic postganglionic cardiac neurons in the guinea pig heart. Therefore, it is possible that the doses of PACAP affect cardiac function through the paracrine system in normal physiological and pathophysiological conditions. The doses of PACAP used in the present study may not represent physiologically relevant serum concentrations of PACAP, but such doses are likely to be required to achieve physiologically relevant concentrations at the receptor level.
In this study, PACAP shortened the atrial refractory period uniformly in the right and left atria. This response to PACAP is distinct from the response to bilateral cervical vagal nerve stimulation, which shortens the refractory period to a greater extent in the right than the left atrium. Evidence from this study and from previous studies indicates that PACAP shortens atrial refractoriness by causing ACh to be released from postganglionic parasympathetic nerves. From these data and those from previous studies, we believe that PACAP most likely stimulates intracardiac parasympathetic nerves to both atria, not all of which are activated by cervical vagal stimulation.
